Cue Biopharma, Inc. (CUE) income statement
CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.15−0.35 (-7.78%)
Close on Nov 20, 2026Market cap $30.15MP/E –Yield –
Cue Biopharma, Inc. financial ratios
See a number that looks wrong?
Close on Nov 20, 2026Market cap $30.15MP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||||
| Operating margin | -96.7% | -446.9% | -949.9% | -4,275.1% | -292.6% | -1,428.0% | -1,063.2% | -3,386.7% | – | – |
| EBITDA margin | -93.2% | -442.6% | -939.8% | -4,201.0% | -284.1% | -1,394.4% | -1,039.8% | -3,320.2% | – | – |
| Pre-tax margin | – | – | – | -4,257.9% | -292.3% | -1,413.3% | -1,049.2% | -3,339.3% | – | – |
| Net profit margin | -96.9% | -438.0% | -924.1% | -4,257.8% | -295.6% | -1,419.8% | -1,061.2% | -3,411.5% | – | – |
| Free cash flow margin | -79.6% | -391.9% | -727.9% | -3,371.6% | -266.0% | -1,049.0% | -891.9% | -2,473.8% | – | – |
| Returns on capital | ||||||||||
| Return on equity | -121.1% | -149.0% | -98.7% | -80.8% | -61.2% | -67.1% | -82.9% | -81.6% | -60.5% | – |
| Return on assets | -71.5% | -86.8% | -66.4% | -60.7% | -48.3% | -52.3% | -62.8% | -69.4% | -34.7% | – |
| Return on tangible assets | -71.5% | -86.8% | -66.4% | -60.7% | -48.3% | -52.3% | -62.8% | -69.4% | -34.7% | – |
| Return on invested capital | – | 808.2% | 2,234.1% | -14,158.3% | -3,162.3% | – | – | – | – | – |
| Return on capital employed | -112.5% | -131.8% | -84.0% | -70.8% | -56.8% | -62.9% | -74.2% | -76.8% | -37.7% | – |
| Return on total capital | – | -132.0% | -86.1% | -75.3% | -66.7% | – | – | – | – | – |
| NOPAT | -$20.98M | -$32.79M | -$41.20M | -$42.05M | -$34.53M | -$35.58M | -$29.05M | -$30.57M | -$18.35M | – |
| Cash flow quality | ||||||||||
| OCF / Sales | -79.0% | -391.2% | -727.9% | -3,357.9% | -259.9% | -1,030.1% | -890.5% | -2,311.5% | – | – |
| OCF / Net income | 0.82 | 0.89 | 0.79 | 0.79 | 0.88 | 0.73 | 0.84 | 0.68 | 0.52 | – |
| FCF / OCF | 100.8% | 100.2% | 100.0% | 100.4% | 102.4% | 101.8% | 100.2% | 107.0% | 108.5% | – |
| FCF / Net income | 0.82 | 0.89 | 0.79 | 0.79 | 0.90 | 0.74 | 0.84 | 0.73 | 0.57 | – |
| FCF / EBITDA | 85.4% | 88.5% | 77.5% | 80.3% | 93.6% | 75.2% | 85.8% | 74.5% | – | – |
| Unlevered free cash flow | -$21.79M | -$36.32M | -$39.88M | -$41.89M | -$39.75M | -$33.09M | -$30.84M | -$28.27M | -$13.17M | – |
| Levered free cash flow | -$21.86M | -$36.40M | -$39.96M | -$41.98M | -$39.75M | -$33.09M | -$30.84M | -$28.27M | -$13.17M | – |
| Efficiency | ||||||||||
| Asset turnover | 0.74 | 0.20 | 0.07 | 0.01 | 0.16 | 0.04 | 0.06 | 0.02 | – | – |
| Fixed asset turnover | 77.15 | 14.67 | 4.79 | 0.69 | 7.08 | 1.60 | 1.49 | 0.51 | – | – |
| Receivables turnover | 8.46 | 7.03 | 6.26 | 0.78 | 6.55 | 2.90 | 4.58 | – | – | – |
| Days sales outstanding | 43.1 | 51.9 | 58.3 | 469.0 | 55.7 | 125.7 | 79.7 | – | – | – |
| CapEx to revenue | 0.64% | 0.71% | 0.00% | 13.7% | 6.1% | 18.9% | 1.3% | 162.3% | – | – |
| CapEx to OCF | -0.82% | -0.18% | -0.00% | -0.41% | -2.4% | -1.8% | -0.15% | -7.0% | -8.5% | – |
| CapEx to depreciation | 0.18 | 0.17 | 0.00 | 0.19 | 0.73 | 0.56 | 0.06 | 2.44 | – | – |
| Liquidity | ||||||||||
| Current ratio | 2.74 | 1.84 | 3.01 | 6.68 | 5.35 | 5.36 | 5.24 | 6.53 | 12.17 | – |
| Quick ratio | 2.74 | 1.84 | 3.01 | 6.68 | 5.35 | 5.36 | 5.24 | 6.53 | 12.17 | – |
| Cash ratio | 2.01 | 1.64 | 2.84 | 6.61 | 5.04 | 5.20 | 5.10 | 6.31 | 11.88 | – |
| Working capital | $23.49M | $11.45M | $34.37M | $65.64M | $55.68M | $71.21M | $49.37M | $34.39M | $59.72M | – |
| Net current asset value | $21.20M | $10.45M | $27.01M | $51.59M | $50.56M | $66.91M | $44.00M | $29.22M | $59.72M | – |
| Leverage | ||||||||||
| Total debt | – | $37.00K | $8.24M | $10.11M | $0 | – | – | – | – | – |
| Net debt | – | -$22.42M | -$40.28M | -$66.18M | -$64.40M | – | – | – | – | – |
| Debt / Equity | – | 0.00 | 0.22 | 0.15 | 0.00 | – | – | – | – | – |
| Debt ratio | – | 0.11% | 13.4% | 11.1% | 0.00% | – | – | – | – | – |
| Assets to equity | 1.60 | 1.84 | 1.66 | 1.39 | 1.27 | 1.26 | 1.31 | 1.34 | 1.09 | – |
| Long-term debt to assets | – | 0.00% | 6.8% | 8.8% | 0.00% | – | – | – | – | – |
| Long-term debt to equity | – | 0.00 | 0.11 | 0.12 | 0.00 | – | – | – | – | – |
| Total debt / Capitalization | – | 0.21% | 18.2% | 13.3% | 0.00% | – | – | – | – | – |
| Long-term debt / Capitalization | – | 0.00% | 10.2% | 10.9% | 0.00% | – | – | – | – | – |
| Net debt / EBITDA | – | 0.55 | 0.78 | 1.27 | 1.52 | – | – | – | – | – |
| Total debt / EBITDA | – | -0.00 | -0.16 | -0.19 | -0.00 | – | – | – | – | – |
| Cash flow to debt | – | -98,186.5% | -485.0% | -413.6% | – | – | – | – | – | – |
| Interest coverage | ||||||||||
| EBIT / Interest expense | -265.52 | -415.00 | -521.49 | -488.30 | – | – | – | – | – | – |
| EBITDA / Interest expense | -255.94 | -411.03 | -515.93 | -479.84 | – | – | – | – | – | – |
| (EBITDA − CapEx) / Interest expense | -257.71 | -411.69 | -515.93 | -481.41 | – | – | – | – | – | – |
| Per share | ||||||||||
| Revenue per share | 8.53 | 4.51 | 3.49 | 0.79 | 13.92 | 3.12 | 3.91 | 1.66 | – | – |
| EPS (basic) | -8.40 | -21.60 | -33.30 | -44.70 | -42.30 | -46.80 | -49.80 | -58.20 | -64.80 | – |
| EPS (diluted) | -8.40 | -21.60 | -33.30 | -44.70 | -42.30 | -46.80 | -49.80 | -58.20 | -64.80 | – |
| Book value per share | 8.21 | 8.49 | 23.56 | 41.73 | 61.01 | 78.00 | 61.65 | 49.24 | 94.98 | – |
| Tangible book value per share | 8.21 | 8.49 | 23.56 | 41.73 | 61.01 | 78.00 | 61.65 | 49.24 | 94.98 | – |
| Cash per share | 8.43 | 10.90 | 30.83 | 48.47 | 60.00 | 83.92 | 67.10 | 56.84 | 97.95 | – |
| Operating cash flow per share | -6.73 | -17.63 | -25.39 | -26.56 | -36.18 | -32.12 | -34.78 | -38.28 | -18.72 | – |
| Free cash flow per share | -6.79 | -17.66 | -25.39 | -26.67 | -37.03 | -32.71 | -34.84 | -40.97 | -20.31 | – |
| CapEx per share | 0.05 | 0.03 | 0.00 | 0.11 | 0.85 | 0.59 | 0.05 | 2.69 | 1.59 | – |
| Valuation at period end | ||||||||||
| Market cap | $23.76M | $65.63M | $119.14M | $100.86M | $354.74M | $378.48M | $364.68M | $94.64M | – | – |
| Enterprise value | $5.08M | $38.54M | $73.61M | $51.71M | $287.11M | $286.68M | $333.31M | $55.45M | – | – |
| P/S | 0.9x | 7.1x | 21.7x | 81.0x | 23.7x | 120x | 105x | 82.8x | – | – |
| P/B | 0.9x | 3.8x | 3.2x | 1.5x | 5.4x | 4.8x | 6.7x | 2.8x | – | – |
| P/TBV | 0.9x | 3.8x | 3.2x | 1.5x | 5.4x | 4.8x | 6.7x | 2.8x | – | – |
| P/OCF | -1.1x | -1.8x | -3.0x | -2.4x | -9.1x | -11.6x | -11.8x | -3.6x | – | – |
| EV/Sales | 0.2x | 4.1x | 13.4x | 41.5x | 19.2x | 90.9x | 96.4x | 48.5x | – | – |
| EV/OCF | -0.2x | -1.1x | -1.8x | -1.2x | -7.4x | -8.8x | -10.8x | -2.1x | – | – |
| Earnings yield | -112.0% | -62.0% | -42.6% | -52.6% | -12.4% | -11.8% | -10.1% | -41.2% | – | – |
| FCF yield | -92.0% | -55.5% | -33.5% | -41.6% | -11.2% | -8.7% | -8.5% | -29.9% | – | – |
| Shareholder yield | ||||||||||
| Buyback yield | – | – | 0.00% | 0.20% | 0.21% | -14.9% | -13.4% | – | – | – |
| Shareholder yield | – | – | 0.00% | 0.20% | 0.21% | -14.9% | -13.4% | – | – | – |
| Cost structure | ||||||||||
| R&D to revenue | 137.4% | 390.8% | 743.2% | 3,098.6% | 276.7% | 1,063.5% | 794.8% | 2,498.2% | – | – |
| Stock-based comp to revenue | 17.3% | 73.7% | 149.0% | 762.7% | 77.1% | 332.3% | 188.6% | 627.8% | – | – |
| Per employee | ||||||||||
| Total employees | 29 | 41 | 53 | 51 | 57 | 50 | 45 | 46 | 28 | 28 |
| Revenue per employee | $947.10K | $226.51K | $103.58K | $24.41K | $262.13K | $63.09K | $76.85K | $24.84K | – | – |
| Operating profit per employee | -$915.59K | -$1.01M | -$983.94K | -$1.04M | -$766.88K | -$900.85K | -$817.09K | -$841.23K | -$829.78K | – |
| Net income per employee | -$917.31K | -$992.05K | -$957.23K | -$1.04M | -$774.76K | -$895.70K | -$815.53K | -$847.40K | -$829.78K | – |
| Free cash flow per employee | -$753.93K | -$887.68K | -$753.98K | -$823.08K | -$697.37K | -$661.79K | -$685.41K | -$614.46K | -$470.41K | – |
| Growth | ||||||||||
| Revenue 1Y growth | 195.7% | 69.2% | 341.0% | -91.7% | 373.7% | -8.8% | 202.7% | – | – | – |
| Revenue 3Y CAGR | 180.5% | -14.7% | 20.3% | -28.9% | 135.6% | – | – | – | – | – |
| Revenue 5Y CAGR | 54.2% | 21.8% | 36.9% | – | – | – | – | – | – | – |
| EBIT 1Y growth | 36.0% | 20.4% | 2.0% | -21.8% | 3.0% | -22.5% | 5.0% | -66.6% | – | – |
| EBITDA 1Y growth | 37.7% | 20.3% | 1.4% | -23.2% | 3.5% | -22.3% | 5.2% | – | – | – |
| Net income 1Y growth | 34.6% | 19.8% | 4.3% | -20.0% | 1.4% | -22.0% | 5.9% | -67.8% | – | – |
| Diluted EPS 1Y growth | 61.1% | 35.1% | 25.5% | -5.7% | 9.6% | 6.0% | 14.4% | 10.2% | – | – |
| Operating cash flow 1Y growth | 40.3% | 9.1% | 4.4% | -7.6% | -19.5% | -5.5% | -16.6% | -117.5% | – | – |
| Free cash flow 1Y growth | 39.9% | 8.9% | 4.8% | -5.6% | -20.1% | -7.3% | -9.1% | -114.6% | – | – |
| CapEx 1Y growth | 168.2% | – | -100.0% | -81.3% | 53.4% | 1,184.2% | -97.5% | 80.0% | – | – |
| CapEx 3Y CAGR | 1.2% | -58.3% | – | 54.5% | -21.0% | -16.7% | – | – | – | – |
| CapEx 5Y CAGR | -21.5% | 7.3% | – | -30.2% | – | – | – | – | – | – |
| Total assets 1Y growth | 31.1% | -47.7% | -32.6% | 9.5% | -16.2% | 39.0% | 57.8% | -32.2% | – | – |
| Total assets 3Y CAGR | -22.7% | -27.2% | -14.8% | 8.4% | 22.5% | 14.1% | – | – | – | – |
| Total assets 5Y CAGR | -15.8% | -14.8% | 6.3% | 6.4% | – | – | – | – | – | – |
| Total equity 1Y growth | 51.0% | -52.8% | -43.5% | 0.29% | -17.0% | 44.6% | 60.7% | -44.9% | 306.0% | – |
| Total equity 3Y CAGR | -26.2% | -35.6% | -22.3% | 6.4% | 24.5% | 8.6% | 53.2% | – | – | – |
| Total equity 5Y CAGR | -19.6% | -20.3% | 1.8% | 1.3% | 34.0% | – | – | – | – | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.